Evidence map›Paper›PMID 33785364›Full record

ArticleTransplantation and cellular therapy2021

Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation.

Georgios E Christakopoulos, Todd E DeFor, Stefanie Hage, John E Wagner, Michael A Linden, Claudio Brunstein, Nelli Bejanyan, Michael R Verneris, Angela R Smith

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Georgios E ChristakopoulosDepartments of Oncology and Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Todd E DeForBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Stefanie HageDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.
John E WagnerDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.
Michael A LindenDepartment of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota.
Claudio BrunsteinDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.
Nelli BejanyanH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Michael R VernerisDivision of Hematology, Oncology, and Bone Marrow Transplantation, Department of Pediatrics, University of Colorado, Aurora, Colorado.
Angela R SmithDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota. Electronic address: smith719@umn.edu.
University of Minnesota Medical Center · USMoffitt Cancer Center · USSt. Jude Children's Research Hospital · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
INVASIVE GLIOMA CELLSF32CA067493 · NCI · WASHINGTON UNIVERSITY · PI CHICOINE, MICHAEL R · 1995 to 1996
–
NCATS NIH HHS UL1 TR002494NCI NIH HHS F32 CA067493NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598
6 · The paper itself

Abstract

Platelet recovery is delayed after umbilical cord blood transplant (UCBT). Romiplostim is a thrombopoietin receptor agonist that has the potential to improve platelet engraftment after UCBT. The purpose of this study was to determine the safety profile and maximum tolerated dose (MTD) of romiplostim and to investigate whether romiplostim accelerates platelet recovery post-UCBT. It was a single-center, dose-finding, safety and tolerability phase I trial of weekly romiplostim in 20 adult patients who failed to achieve an un-transfused platelet count of 20 × 10

Indexed as

Receptors, FcThrombopoietinAdultBlood PlateletsFemaleHumansMiddle AgedRecombinant Fusion ProteinsReceptors, FcRecombinant Fusion ProteinsromiplostimThrombopoietinDelayed platelet recoveryRomiplostimUmbilical cord blood transplantation

Identifiers

PMID33785364
PMCPMC8217114
OpenAlexW3134397300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.